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Abstract
Mast cells are immune cells critical in the pathogenesis of allergic, but also inflammatory and autoimmune diseases through
release of many pro-inflammatory cytokines such as IL-8 and TNF. Contact dermatitis and photosensitivity are skin
conditions that involve non-immune triggers such as substance P (SP), and do not respond to conventional treatment.
Inhibition of mast cell cytokine release could be effective therapy for such diseases. Unfortunately, disodium cromoglycate
(cromolyn), the only compound marketed as a mast cell ‘‘stabilizer’’, is not particularly effective in blocking human mast
cells. Instead, flavonoids are potent anti-oxidant and anti-inflammatory compounds with mast cell inhibitory actions. Here,
we first compared the flavonoid quercetin (Que) and cromolyn on cultured human mast cells. Que and cromolyn (100 mM)
can effectively inhibit secretion of histamine and PGD2. Que and cromolyn also inhibit histamine, leukotrienes and PGD2
from primary human cord blood-derived cultured mast cells (hCBMCs) stimulated by IgE/Anti-IgE. However, Que is more
effective than cromolyn in inhibiting IL-8 and TNF release from LAD2 mast cells stimulated by SP. Moreover, Que reduces IL-
6 release from hCBMCs in a dose-dependent manner. Que inhibits cytosolic calcium level increase and NF-kappa B
activation. Interestingly, Que is effective prophylactically, while cromolyn must be added together with the trigger or it
rapidly loses its effect. In two pilot, open-label, clinical trials, Que significantly decreased contact dermatitis and
photosensitivity, skin conditions that do not respond to conventional treatment. In summary, Que is a promising candidate
as an effective mast cell inhibitor for allergic and inflammatory diseases, especially in formulations that permit more
sufficient oral absorption.
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Introduction
Mast cells derive from hematopoietic progenitors and mature in
tissues depending on microenvironmental conditions [1,2]. Mast
cells are important effector cells in allergic reactions [3–6] by
secreting histamine, leukotrienes (LTs), prostaglandin D2 (PGD2),
proteolytic enzymes and several multifunctional cytokines, such as
interleukin-6 (IL-6), IL-8, IL-13, tumor necrosis factor (TNF), and
vascular endothelial growth factor (VEGF) [7–9]. These mediators
contribute to the late-phase reactions and to inflammation through
the recruitment and activation of immune cells [10,11]. In
addition to IgE and antigen, anaphylatoxins, cytokines, hormones
and neuropeptides, such as substance P (SP), can trigger mast cell
secretion [12] of several mediators often selectively [13]. More
importantly, SP has been implicated in many skin inflammatory
disorders, including contact dermatitis [14,15]. As a result, mast
cells are also involved in innate and acquired immunity [16], as
well as autoimmunity and inflammation [12], especially in the skin
[17,18]. Mast cells were also shown to be involved in contact
dermatitis in mice [19,20].
Mast cells play an essential role in contact hypersensitivity
through a complex interaction with different kinds of immune
cells, including antigen presenting cells, T, B, NK lymphocytes,
keratinocytes, endothelium, and platelets [21]. In allergic contact
dermatitis, mast cells regulate the inflammatory reactions by
releasing mediators like histamine, TNF-a and IL-8, leading to
local vascular activation and subsequent immune cell recruitment
[22]. Contact dermatitis and photosensitivity are difficult to treat
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(cromolyn) has failed in these diseases [25]. Several studies even
reported development of contact dermatitis from cromolyn-
containing eyedrops [26,27]. Here we compared the ability of
quercetin and cromolyn to inhibit key mediators from human
cultured mast cells stimulated by SP or IgE/Anti-IgE, as well as
the effect of quercetin on contact dermatitis and photosensitivity in
humans.
There are no effective clinically available mast cell inhibitors. In
vitro, cromolyn inhibits rodent peritoneal mast cell histamine
secretion [28], but could not inhibit rat mucosal mast cells even
at 1000 mM [29,30]. Moreover, 1000 mM cromolyn was required
for any inhibition of histamine release from human lung and
tonsillar mast cells [31]. Even though, cromolyn was ineffective in
inhibiting human lung and intestinal mast cells [32]. Cromolyn is
used in the management of mastocytosis to relieve diarrhea and
abdominal cramping [33]. Intestinal absorption of cromolyn is
severely limited (#1%), and several weeks of therapy may be
needed before any clinical benefits are seen [34]. This finding goes
against the well known phenomenon of tachyphylaxis exhibited
during cromolyn pretreatment [28].
Certain naturally occurring flavonoids, such as quercetin (Fig.
S1B), are polyphenolic compounds found in fruits, vegetables,
nuts, seeds, herbs, spices and red wine with antioxidant properties
[35–37]. Flavonoids have potent anti-oxidant, anti-inflammatory
[38], and mast cell blocking activities [39,40]. Several flavonoids
can inhibit histamine release from murine mast cells [41,42], as
well as IL-6 and TNF release from bone marrow-derived cultured
murine mast cells and rat peritoneal mast cells [43]. Quercetin and
its structurally related luteolin inhibit the release of histamine,
leukotrienes and PGD2 from human cultured mast cells in
response to cross-linkage of high affinity surface IgE receptors
(FceRI) [44]. Quercetin also inhibits histamine, IL-6, IL-8, TNF-a
and tryptase release from human mast cells [39,40], as well as
asthma development in an animal model [45]. Quercetin could
inhibit stimulated rat peritoneal mast cells by 75% at 10 mM, while
1000 mM of cromolyn was required for 65% inhibition [46].
However, quercetin was never compared to cromolyn on human
mast cell mediator release in response to either an allergic or non-
immune trigger.
Here we show that quercetin is more effective than cromolyn in
inhibiting inflammatory cytokine release from human cultured
mast cells.
Results
Effect on primary hCBMC cell histamine, PGD2 and
leukotriene release
Stimulation of hCBMCs with IgE/Anti-IgE results in rapid
secretion of large amounts ofhistamine, PDG2andLTs (Fig.1A–C).
Preincubation with Que or WSQ (100 mM) significantly reduce
histamine secretion (Fig. 1A) from 4347.9 to 977.3 pg/mL (82%
inhibition), and to 797.7 pg/mL (87% inhibition), respectively,
compared to cromolyn (1613.6 pg/mL, 67% inhibition). Que and
WSQ inhibit PGD2 release (Fig. 1B) from 3771.8 to 882.5 pg/mL
(77% inhibition), and to 740.8 pg/mL (81% inhibition), respectively,
Figure 1. Quercetin and cromolyn inhibit degranulation of hCBMCs triggered by IgE/Anti-IgE. Cells were treated with IgE (100 ng/mL)
for 2 hr and then stimulated with Anti-IgE (1 mg/mL) for 2 hr. In some experiments, cells were pre-incubated with Que or WSQ (100 mM, 30 min), or
treated with cromolyn (100 mM) together with Anti-IgE. (A) Histamine; (B) PGD2; (C) Leukotriene. n=3, * indicates p,0.05, ** indicates p,0.01.
WSQ=water soluble quercetin; Que=quercetin; Crom=cromolyn.
doi:10.1371/journal.pone.0033805.g001
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QueandWSQblockLTsecretion(Fig.1C)from4628.6to35.3 pg/
mL (99% inhibition), and to 29.7 pg/mL (99% inhibition),
respectively, compared to cromolyn (530.9 pg/mL, 88% inhibition).
Cells were .95% viable after 24 hr incubation with the drugs (Fig.
S2A). Que was effective when added 30 min prior to the trigger. No
significant inhibitory effect was observed when Que was added
togetherwiththetrigger(Fig.S3A–C).However,cromolynhad tobe
added together with the trigger for any inhibitory effect to be
evident (Fig. S4).
Effect on human mast cell histamine, IL-8, TNF and IL-6
release
LAD2 mast cells release histamine 2 hr after SP (2 mM)
stimulation (1611.4 pg/mL, Fig. 2A). WSQ inhibits histamine
release to 350.6 pg/mL, which is even lower than that of control
(388.7 pg/mL). Quercetin and cromolyn reduce histamine release
to 792.3 pg/mL and 464.6 pg/mL, respectively (Fig. 2A). LAD2
mast cells also secrete newly-synthesized IL-8 and TNF 24 hr after
SP (2 mM) stimulation. Incubation with WSQ, quercetin and
cromolyn (100 mM) effectively block secretion of IL-8 from
437.2 pg/mL to 115.4 pg/mL, 291.2 pg/mL and 362.9 pg/mL,
respectively. Similarly, WSQ, quercetin and cromolyn (100 mM)
block TNF secretion from 1917.2 pg/mL to 274.7 pg/mL,
436.9 pg/mL and 1628.8 pg/mL, respectively (Fig. 2B&C).
WSQ is the most effective while cromolyn is the least effective.
Primary hCBMCs release IL-6 (223.5 pg/mL) 24 hr after
stimulation with IgE/Anti-IgE, and is inhibited by quercetin in a
dose-dependent manner (Fig. 2D). Quercetin preincubation at 10
and 100 mM for 30 min reduces IL-6 release to 65.8 pg/mL and
29.7 pg/mL, respectively, which is even lower than that of control
(96.8 pg/mL, Fig. 2D). Cromolyn (100 mM) is able to decrease IL-
6 release to 141.3 pg/mL.
It should be noted again that, when added together with the
trigger, quercetin does not exhibit any significant inhibitory effect
on SP-triggered mediator release from LAD2 cells (Fig. S3D–F).
After 30 min preincubation, cromolyn has no effect due to rapid
tachyphylaxis (Fig. S4). Instead, cromolyn had to be added
together with SP for any inhibitory effect to be evident. Cells
were .95% viable after 24 hr incubation with the drugs (Fig. S2B).
Effect on intracellular calcium increase in human mast
cells
In order to investigate the possible mechanism of action of these
agents, we studied the effect on intracellular calcium ions.
Preincubation with WSQ (100 mM, 30 min) completely inhibits
the intracellular calcium ion increase as compared to equimolar
concentration of quercetin (Fig. 3), which is half as active.
Figure 2. Quercetin inhibits SP-triggered mediator release from human mast cells. LAD2 cells were stimulated with SP (2 mM). In some
experiments, cells were pre-incubated with Que or WSQ (100 mM, 30 min), or treated with cromolyn (100 mM) together with SP. (A) Histamine; (B) IL-8;
(C) TNF. In (D) IL-6; hCBMCs were treated with either 100 mM cromolyn together with the trigger, or pre-incubated with increasing concentrations of
quercetin for 30 min, then stimulated with IgE/Anti-IgE as described in Fig. 1. Histamin release was measured at 2 hr. Cytokine release was measured
at 24 hr. n=3, * indicates p,0.05.
doi:10.1371/journal.pone.0033805.g002
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together with the trigger (data not shown).
Effect on NF-kB nuclear translocation in LAD2 mast cells
Cytocolic NF-kB protein levels do not change much before and
after SP stimulation (Fig. 4). SP induces NF-kB translocation into
the nucleus within 60 min compared to control. This NF-kB
nuclear translocation is inhibited by 30 min preincubation with
WSQ, which is more effective than quercetin and cromolyn (Fig. 4).
Effect on contact dermatitis and skin photosensitivity in
humans
Patch tests conducted with nickel in 10 volunteers showed
extensive dermatitis ranging from 1+ to 3+ at 48 hr and 120 hr
after nickel contact (Fig. 5A&B). Pre-administraiton of WSQ (2 g/
day for 3 days) before nickel contact on the same volunteers
effectively reduced this reaction by more than 50% in 8 out of 10
patietns, and 100% in the other 2 patients (Fig. 5A&B, Wilxocon
paired non-parametric test, p=0.039 for 48 hr, and p=0.031 for
120 hr after nickel contact). Moreover, any associated pruritus
disappeared as did the generalized pruritus present in one patient
with pre-exsiting atopic dermatitis.
As shown in Fig. 6, administration of 1 g WSQ increases the
MED to induce skin erythema 24 hours after irradiation in all
patients (Wilcoxon paired non-parametric test, p=0.002). MED is
defined as the minimal dose that induces any visible reddening. An
increase in MED demonstrates increased resistance to develop skin
reddening after UVB irradiation.
Discussion
Here we report on the comparative inhibitory effect of WSQ,
Que and the ‘‘mast cell stabilizer’’ cromolyn on human mast cell
secretion of inflammatory mediators. Que is equally effective to
cromolyn in inhibiting histamine, PGD2 and LT release but much
more effective in reducing cytokine release from human mast cells.
The limited number of mast cells obtained from normal human
tissues has led to increasing use of human leukemic cultured LAD2
cells[47] orhumanumbilicalcord blood-derived cultured mastcells
(hCBMCs) previously reported to release cytokines, histamine and
tryptase in response to anti-IgE [48,49]. In the present study, we
used IgE/Anti-IgE as a positive mast cell trigger for hCBMCs, and
SP for LAD2 cells. We chose to do so because recent studies have
implicated sensory neuropeptides, such as SP, in the pathogenesis of
many skin diseases, including contact dermatitis [14,15].
Figure 3. Quercetin inhibits intracellular calcium levels in SP-stimulated LAD mast cells. Cells were loaded with Fura-2 AM (30 nM,
20 min) and then pre-incubated with flavonoids (100 mM, 30 min). Immediately after SP addition (2 mM), Fura-2 AM fluorescence was detected for
20 min.
doi:10.1371/journal.pone.0033805.g003
Figure 4. Quercetin inhibits nuclear translocation of NF-kBi n
LAD2 mast cells. Cells were pretreated with drugs (100 mM, 30 min)
and then stimulated by SP (2 mM, 60 min). Upper lane, NF-kB protein
levels in nuclear fractions before and after SP stimulation; Middle lane,
NF-kB protein levels in cytosolic fractions before and after SP
stimulation.
doi:10.1371/journal.pone.0033805.g004
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secretion from rodent peritoneal mast cells, but was a much
weaker inhibitor of human mast cells [31,50]. Moreover, cromolyn
does not inhibit lung and mucosal mast cells [31,32]. Cromolyn
was previsouly shown to inhibit TNF release from rat peri-
toneal mast cells by only 20% at 100 mM [51] and 1000 mM
concentration was reported for any inhibition of human lung mast
cells [31]. Clinically, cromolyn has been used in the management
of mastocytosis [33,52] and other allergic diseases, including atopic
dermatitis [53,54]. Although mast cell stabilization was initially
considered as its mechanism of action, modulation of sensory
nerve fiber activation has also been suggested. For instance, topical
cromolyn treatment effectively reduces allergen-induced pruritus
but has no effect on weals, supporting that in the skin, cromolyn
inhibits sensory C-fiber nerve activation rather than inhibiting
mast cell degranulation [55]. Instead, Que and luteolin were
shown to inhibit histamine, IL-6 and TNF production from bone-
marrow derived cultured murine mast cells [43]. Quercetin had
also been reported to inhibit histamine release from rat connective
tissue mast cells and mucosal mast cells [56], as well as from
human lung and intestinal mast cells [32].
Here we also show that WSQ is more effective than quercetin in
blocking intracellular calcium increases in stimulated human mast
cells, while cromolyn had no effect. WSQ and Que are appear to
be more effective than cromolyn in inhibiting NF-kB nuclear
translocation, which is necessary for the production of pro-
inflammatory cytokines. However, our results are not quantitative
because we did not perform a reporter gene assay. Previous studies
Figure 5. Inhibitory effect of WSQ on nickel patch tests. Examination of patch tests was done at 48 hr and 120 hr after application of the
patch containing nickel first without WSQ and then one week later, 3 days after having taken WSQ (2 g/day). (A&B) Individual patient data from nickel
patch tests were analyzed by the Wilcoxon paired non-parametric test. Representative patch test from patient No. 8 is shown in C–F. Appearance at
(C) 48 hr or (D) 120 hr without WSQ. (E) 48 hr or (F) 120 hr during which patient was administered WSQ. White arrows indicate the area of nickel
patch test. It should be noted that associated pruritus (itching) was eliminated in all subjects, along with widespread itching in one patient who also
had chronic atopic dermatitis.
doi:10.1371/journal.pone.0033805.g005
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intracellular calcium levels [48,57], a necessary step for mediator
release [58]. Fewtrell and Gomperts first showed that Que could
inhibit calcium influx in rat peritoneal mast cells [59]. Previous
reports showed that IgE-mediated release of histamine and
leukotrienes was abolished after calcium depletion [60]. Que also
inhibited ionophore-induced histamine release from rat peritoneal
mast cells, suggesting it had actions other than receptor-mediated
calcium influx [46]. The structure of Que has some similarity to
that of cromolyn (Fig. S1), but their actions appear to differ
considerably. Not only is Que more effective than cromolyn, but
Que inhibits intracellular calcium increases, while cromolyn does
not. An additional important difference is that Que is effective
prophylactically, but not when added together with the trigger,
while cromolyn shows inhibition only when added together
with the trigger. The lack of cromolyn’s inhibitory action when
used prophylactically was reported before and was termed
tachyphylaxis. In fact, cromolyn’s inhibitory action and tachyphy-
laxis were related to the phosphorylation of moesin [61,62], which
also showed tachyphylaxis with cromolyn pre-incubation in
stimulated rat peritoneal mast cells [28,62]. Que also stimulated
phosphorylation of moesin in rat peritoneal mast cells [63].
Here we report for the first time to our knowledge that Que can
be beneficial in contact dermatitis and photosensitivity in humans,
conditions that are typically difficult to treat [64,65]. Cromolyn
was not tried in either one of these two models. There is only
one publication from 1990 where patients with nickel-positive
pompholyx (skin reactions even in the absence of contact with
nickel) ‘‘reacted better’’ after prolonged (15 days) treatment with
oral cromolyn [66]. The in vitro concentration of cromolyn we used
(100 mM) is approximately 10 times more than the concentration
administered in humans assuming even distribution of 400 mg
oral cromolyn (molecular weight 460) in a 80 kg human per day.
The in vitro concentration of quercetin (molecular weight 300) we
used (100 mM) is almost identical to that administered to humans
(1 g/day) in these two pilot studies.
The apparent beneficial effect of quercetin in these skin
conditions could be extended to atopic dermatitis/eczema and
psoriasis that are also difficult to treat and involve both
neuropeptides and mast cells [67,68]. The burden of these
diseases to the economy is estimated at about $ 5b i l l i o n / y e a r .
Mast cells have been implicated in allergic and inflammatory
diseases of the skin [17,18]. Contact dermatitis involves both
mast cells and T cells [22]. In this context, it is interesting that
mast cells were reported to stimulate activated T cells [69,70],
one effect requiring TNF and blocked by the flavone luteolin
[69]. Moreover, mast cells have the ability to present antigen
[71] and to regulate dendritic cell trafficking through TNF
[ 7 2 ] .I nf a c t ,m a s tc e l li st h eo n l yc e l lt y p et h a ts t o r e sp r e -
formed TNF [12].
Skin photosensitivity is a rapid reaction that is due to both
keratinocyte, mast cell and sensory nerve activation [73,74]. In this
context, it is important to mention that mast cells are in close
contact with sensory nerve endings in the skin [75], and can be
activated by sensory neuropeptides [76]. In turn, mast cell-derived
mediators such as histamine and TNF can stimulate sensory nerve
endings [77,78].
Flavonoids had been reported to improve allergic symptoms or
prevent the development of allergic diseases [79,80]. Moreover,
oral administration of astragalin, which is absorbed and converted
into kaempferol, suppresed the onset of dermatitis in NC/Nga
mice [81]. In a phase I clinical trial of Que, a dose of 2.5 g for a
70 kg individual administered via intravenous infusion at 3-week
or weekly intervals was recommended for Phase II trials [82]. The
Que dose used in humans in the present study (2 g/day) is
clinically relevant. A major drawback of the use of Que and
cromolyn in the clinical setting is their poor water solubility.
Previsous studies showed that the oral absorption of quercetin and
cromolyn is only 1% [83] and 1–5% [84] respectively. WSQ is
soluble in aqueous medium only, but is likely to precipitate in the
acidic environment of the stomach while used in vivo. A liposomal
or enteric coated formulation may offer advantage for increased
bioavailability. A phytoquercetin is now under development and
appears to have much higher oral absorption.
In conclusion, our results indicate that quercetin is more
effective than cromolyn in inhibiting release of pro-inflammatory
cytokines from human mast cells. Moreover, quercetin appears to
significantly reduce contact dermatitis, photosensitivity and
associated pruritus that are typically resistant to anti-histamines
and cromolyn [85,86]. Quercetin is safe [87] and could be
particularly useful in formulations that increase its solubility and
oral absorption.
Figure 6. Inhibitory effect of WSQ on skin photosensitivity. (A)
Energy fluence values at MED estimated 24 hr after irradiation with and
without WSQ (1 g). Data was analyzed by Wilcoxon paired non-
parametric test. Photos show three difference spots on the medial
aspect of the forearm, representing three different energy fluence
values of UVB broad band irradiation (UVB 801, Waldmann, 3.03 mW at
21 cm). (B) Skin appearance 24 hr after irradiation with WSQ
administration (1 g). (C) Skin appearance 24 hr after irradiation without
WSQ administration. White arrows indicate spots of UVB irradiation.
doi:10.1371/journal.pone.0033805.g006
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Drugs and Reagents
Recombinant human stem cell factor (rhSCF) was kindly
donated by Biobitrum AB, (Stockholm, Sweden). Cromolyn,
quercetin and SP were obtained from Sigma-Aldrich (St Louis,
MO). A sodium salt of quercetin soluble in water at pH 7.4 or
higher (WSQ) was provided by Thorne Research, Inc. (Dover,
ID). All drugs were dissolved in DMSO, except for WSQ, which
was dissolved in double-distilled water forming a solution of
pH<9. Final concentration of DMSO was ,0.1% and pH
was 7.4. Rabbit anti-NF-kB (p65, RelA) (Ab-1) antibody was
purchased from Millipore (Billerica, MA), rabbit anti-actin
antibody and the secondary HRP-conjugated antibody were
purchased from Cell Signaling Technology (Beverly, MA).
Human mast cell culture
LAD2 human mast cells (obtained from Dr. A Krisherbaum,
NIH) were cultured in serum-free media (StemPro-34, Gibco,
Grand Island, NY) supplemented with 2 mM L-glutamine,
100 IU/mL penicillin, 50 mg/mL streptomycin, and 100 ng/mL
rhSCF. For optimal cell growth, LAD2 cell density was
maintained between 0.5610
6 and 1610
6 cells/mL.
In order to obtain primary human umbilical cord blood-derived
cultured mast cells (hCBMCs), human cord blood was obtained
from placenta during normal deliveries at Tufts Medical Center in
accordance with established institutional guidelines [88]. Briefly,
mononuclear cells were isolated by layering heparin-treated cord
blood onto Lymphocyte Separation Medium (INC Biomedical,
Aurora, OH). CD34+ progenitor cells were isolated from
mononuclear cells by positive selection of AC133 (CD133+/
CD34+) cells by magnetic cell sorting (Miltenyi Biotech, Auburn,
CA). hCBMCs were derived by the culture of CD34+ progenitor
cells with minor modifications. For the first six weeks, CD34+ cells
were cultured in AIM medium (Gibco, Grand Island, NY)
supplemented with 100 ng/mL rhSCF, after six weeks of culture,
50 ng/mL IL-6 (Chemicon) was added. Cells were cultured at
37uCi n5 %C O 2 balanced air. Mast cell viability was determined
by trypan blue (0.3%) exclusion and was better than 98%.
Mast cell stimulation
LAD2 cells were washed with DPBS and resuspended in
complete culture medium. LAD2 cells (1610
5 cells/200 mL/well)
were plated in 96 well flat bottom Falcon cell culture plates from
Becton Dickinson (Franklin Lakes, NJ), and then stimulated with SP
(2 mM) for 24 hr at 37uCi n5 %C O 2 incubator. Primary hCBMCs
(1610
5 cells/200 mL/well) were stimulated with IgE (100 ng/mL)
for 2 hr followed by Anti-IgE (1 mg/mL) for another 2 hr. Control
cells were treated with equal volume of culture medium only. The
supernatant fluid was collected for further assays.
Degranulation assays
Mast cell degranulation was assessed by measuring histamine,
PGD2 and LTs release in the supernatant fluid 30 min after cell
stimulation. Histamine levels were assayed using a SPI Bio
histamine EIA kit (Bertin Pharma, France). PGD2 release was
measured using a PGD2-MOX EIA kit (Cayman Chemical Co.,
Ann Arbor, MI). LTs levels were assayed using a Luminex
cysteinyl leukotriene kit (Cayman Chemical Co.) according to the
manufacturer’s instructions.
TNF and IL-8 release assays
IL-8 and TNF release into the supernatant fluid 24 hrs after cell
stimulation were measured by Enzyme-Linked Immunosorbent
Assay (ELISA) using a commercial kit from R&D Systems
(Minneapolis, MN) as per the instructions. The minimum
detectable level of IL-8 and TNF was 5 pg/mL.
Cytosolic calcium measurements
Cytosolic calcium was measured at 37uC using Fura-2 as
indicator. LAD2 cells were loaded in Tyrode’s buffer with 30 nM
Fura-2 AM (Invitrogen) for 20 min to allow Fura-2 to enter the
cells. After centrifugation to remove excess dye, the cells were
resuspended in Tyrode’s buffer at a concentration of 10
6 cells/mL
and incubated for another 20 min. Cells were then transferred to
96-well plates with 100 mL per well. SP (2 mM) was added to cells
for the time indicated. Fura-2 fluorescence was read by MDC
FlexStation II (Molecular Devices) at an excitation wavelength of
340 nm/380 nm and emission wavelength of 510 nm. Results
were processed according to the Invitrogen Fura-2 protocol and
reported as relative value of OD 340/380.
NF-kB nuclear translocation assay
After preincubation with different drugs (100 mM, 30 min),
LAD2 mast cells (2610
5 cells per well) were stimulated with SP
(2 mM) for 60 min. Nuclear fractions were isolated using a NE-
PER nuclear extraction kit (Thermo Scientific, Rockford, IL).
Changes in NF-kB protein levels in both cytosolic and nuclear
fractions were detected by Western blot analysis. The protein
concentrations were determined using Bio-Rad Protein Assay
reagent, and equal amounts of protein were subjected to Western
blotting by using the indicated antibodies. Briefly, samples
separated by SDS/PAGE were transferred to nitrocellulose
membranes. After being blocked in 5% BSA (w/v) at room
temperature for 1 hr, the membranes were rinsed and incubated
at 4uC overnight with a variety of primary antibodies (1:1,000
dilution). The membranes were then washed and incubated with
secondary antibody (1:2,000 dilution) at room temperature for
1 hr, developed with chemiluminescence ECL reagent (LumiGold,
SignaGen Laboratories, Gaithersburg, MD), and exposed to
Hyperfilm MP (GE Healthcare, Piscataway, NJ).
Nickel-contact dermatitis in human subjects
Patch tests were performed to volunteers (n=10, all female, age
30–42 years old) sensitive to contact with nickel before and after
taking 2 g/day WSQ (46500 mg/day) orally for 3 days. The
patch containing nickel was first applied without pre-treatment of
WSQ. Examination of the skin site of patch tests was done and
photographs obtained at 48 and 120 hr after application of the
patch. After one-week wash-out period, the same subjects were
given 3 days WSQ as noted above before applying the patch again
to the same arm a few cm distance from the previous site.
Examination of the skin site of patch tests was again done at 48
and 120 hr after application of the patch. Results were recorded as
scores ranging from 1 to 3, with 1 being the least affected and 3
being the worst affected condition. Skin sites were analyzed with
no identifiers. Written consents have been obtained from all
participants. This protocol was approved by the Human Ethics
Review Committee of A. Sygros Hospital of Athens University
Medical School.
Skin photosensitivity in human subjects
Minimal erythema dose (MED) that induces visible reddening
was measured in the medial aspect of the forearm in three different
spots (,2c m
2) of different power fluence values of UVB broad
band irradiation (UVB 801, Waldmann, 3.03 mW at 21 cm).
First, the skin was irradiated without WSQ administration. Skin
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irradiation. After one-week wash-out period, the same subjects
were irradiated at three skin spots close to the previous irradiated
sites with MED and higher power fluence values of UVB broad
band irradiation 2 hr after administration of 1 g WSQ
(46250 mg) orally. Skin erythema was again evaluated and
photographed 24 hr after irradiation. All subjects were females,
age 42.6612.2 years. Skin erythema was evaluated with no
identifiers. Written consents have been obtained from all
participants. This protocol was approved by the Human Ethics
Review Committee of A. Sygros Hospital of Athens University
Medical School.
Statistical analysis
All in vitro conditions were performed in triplicates, and all
experiments were repeated at least three times (n=3). Results are
presented as mean6SD. The results on mediator release are
presented as percent inhibition to normalize baseline differences
between cultures that might be due to variation among the
individual batches of hCBMCs obtained from different donors, as
previously reported [89,90]. Data from stimulated and control
samples were compared using the unpaired, two-tailed, Student’s
t-test. The in vivo patient data were analyzed using two-tailed,
Wilxocon matched pairs test with representative photos showing
affected and unaffected sites. Significance of comparisons is
denoted by p,0.05.
Supporting Information
Figure S1 Structures of cromolyn and quercetin. Circles
indicate the structural similarity between cromolyn and quercetin.
Rectangle indicates the hydroxyl group critical for inhibitory
activity.
(TIF)
Figure S2 Viability of hCBMC and LAD2 mast cells.
hCBMC (A) and LAD2 (B) cells were treated with different drugs
as indicated in Fig. 1 & 2 for 24 hr. Cell viability was checked
using the Trypan Blue exclusion test. Numbr of viable cells are
presented as a percentage of the total cell number. n=3.
(TIF)
Figure S3 Quercetin loses its inhibitory effects on
human mast cells when added together with the trigger.
Human mast cells were stimulated as described in Fig. 1 & 2. In
some experiments, cells were treated with WSQ or Que (100 mM)
together with the trigger without pre-incubation. (A–C) hCBMCs;
(D–F) LAD2. n=3.
(TIF)
Figure S4 Cromolyn does not show significant inhibi-
tion on human mast cells when added 30 min prior to
the trigger. Human mast cells were stimulated as described in
Fig. 1 & 2. In some experiments, cells were treated with Crom
(100 mM) 30 min prior to the trigger. (A–C) hCBMCs; (D–F)
LAD2. n=3.
(TIF)
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